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Abstract
The human oxidative phosphorylation (OxPhos) system consists of approximately 90 proteins encoded by nuclear and
mitochondrial genomes and serves as the primary cellular pathway for ATP biosynthesis. While the core protein machinery
for OxPhos is well characterized, many of its assembly, maturation, and regulatory factors remain unknown. We exploited
the tight transcriptional control of the genes encoding the core OxPhos machinery to identify novel regulators. We
developed a computational procedure, which we call expression screening, which integrates information from thousands of
microarray data sets in a principled manner to identify genes that are consistently co-expressed with a target pathway
across biological contexts. We applied expression screening to predict dozens of novel regulators of OxPhos. For two
candidate genes, CHCHD2 and SLIRP, we show that silencing with RNAi results in destabilization of OxPhos complexes and a
marked loss of OxPhos enzymatic activity. Moreover, we show that SLIRP plays an essential role in maintaining
mitochondrial-localized mRNA transcripts that encode OxPhos protein subunits. Our findings provide a catalogue of
potential novel OxPhos regulators that advance our understanding of the coordination between nuclear and mitochondrial
genomes for the regulation of cellular energy metabolism.
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Introduction
Mitochondrial oxidative phosphorylation (OxPhos) is central to
energy homeostasis and human health by serving as the cell’s
primary generator of ATP. The core machinery underlying
OxPhos consists of approximately 90 distinct protein subunits that
form five complexes residing in the inner mitochondrial
membrane. Complexes I through IV comprise the oxygen-
dependent electron transport chain responsible for driving the
generation of ATP by complex V. OxPhos is the only process in
the mammalian cell under dual genetic control: thirteen essential
structural subunits are encoded by mitochondrial DNA (mtDNA)
while remaining subunits are encoded by nuclear genes, and are
imported into mitochondria [1]. The biogenesis of OxPhos
requires many accessory factors responsible for replicating mtDNA
as well as transcribing and translating the mitochondrial mRNAs
(mtRNA) [2,3]. Furthermore, the mtDNA-encoded subunits must
be coordinately assembled with the nuclear-encoded subunits and
metal co-factors to form functional complexes, a process likely
requiring far more assembly factors than are currently known [4].
Dysfunction in any of these processes or in the OxPhos machinery
itself may result in a respiratory chain disorder, a large class of
inborn errors of metabolism [5]. For approximately 50% of
patients with respiratory chain disorders, the underlying genetic
defect remains unknown, despite excluding obvious members of
the OxPhos pathway [4,6–8]. Many of these disorders are likely
due to genetic defects in currently uncharacterized OxPhos
assembly or regulatory factors.
The OxPhos structural subunits exhibit tight transcriptional
regulation that offers a strategy for identifying its non-structural
regulators based upon shared patterns of co-expression in micro-
array experiments [9,10]. In fact, our laboratory used this approach
to identify the gene LRPPRC, which encodes a critical regulator of
mtRNA and when mutated is the underlying cause of a respiratory
chain disorder called Leigh Syndrome French-Canadian variant
[11]. However, while successful in identifying LRPPRC,t h i s
previous analysis used only one data set interrogating tissue-specific
gene expression [12,13]. Such co-expression analyses that rely upon
individual contexts are not ideal for functional prediction because
they are subject to inherent limitations of microarray experiments
including technical artifacts, experimental bias and real but
confounding correlations with functionally distinct pathways [14].
To overcome these limitations and to generalize our previous
approach, we reasoned that large-scale integration across many
independent microarray experiments, each surveying a different
biological context, would help distinguish genuine co-regulation from
PLoS Genetics | www.plosgenetics.org 1 August 2009 | Volume 5 | Issue 8 | e1000590random co-expression by identifying genes that consistently co-
express with OxPhos. In the yeast Saccharomyces cerevisiae, several
groups have performed such expression data integration studies to
predict protein function [15–17]. With the recent availability of large
repositories of mammalian microarray data, it is now possible to
apply similar approaches to functionally classify uncharacterized
human proteins [18,19]. Studying mammalian data is especially
important for OxPhos given that the mammalian OxPhos pathway
differs significantly from the yeast counterpart. For example, S.
cerevisiae lacks a proton pumping complex I, the largest OxPhos
complex in human cells consisting of forty-five distinct protein
subunits [20] and a common target of respiratory chain disease
[21,22]. Furthermore, mammalian mtDNA is circular, whereas yeast
mtDNA can form linear concatemers [23]. Moreover, mammalian
mtRNA processing differs markedly from S. cerevisaie as mammalian
mtRNA does not contain introns and is polyadenylated [24].
In the present paper, we introduce a computational methodology,
called ‘‘expression screening’’, that takes advantage of the growing
wealth of freely available mammalian microarray data to search for
genesthatexhibitconsistentco-expressionwithagiven‘‘query’’gene
set. Applying this procedure to the mammalian OxPhos pathway
revealed a number of putative regulators that now emerge as
attractive candidate genes for OxPhos disorders. We experimentally
validated two genes, CHCHD2 (coiled-coil-helix-coiled-coil-helix
domain containing 2) and SLIRP (SRA-stem loop interacting RNA-
binding protein; also known as C14orf156) as essential for OxPhos
function. We further characterized SLIRP as a RNA-binding
domaincontainingproteinnecessaryforthemaintenanceofmtRNA
protein-encoding transcripts and whose robust co-expression with
the nuclear OxPhos subunits provides a putative regulatory link
between nuclear and mitochondrial gene expression.
Results
We developed a computational procedure called ‘‘expression
screening’’ (Figure 1), which applies large-scale co-expression
analysis to a compendium of microarray experiments to predict
genes with a functional role in a given pathway, such as OxPhos.
We first assembled a compendium of microarray data sets by
downloading publicly available expression data from the NCBI
Gene Expression Omnibus [18]. We focused on mammalian
biology by selecting human and mouse data, and avoided cross-
platform discrepancies by limiting our analysis to data from
Affymetrix oligonucleotide arrays. To ensure high quality data was
used in downstream co-expression analyses, we removed small
(n,6) data sets and duplicated experiments. Since previous studies
have largely focused on tissue-specific gene expression [10,11,13]
we decided to instead focus on datasets that measure changes in
gene expression within individual tissues or cell types in response
to various stimuli. We therefore excluded data sets containing
multiple tissues. These filtering steps resulted in a final compen-
dium of 1,427 microarray data sets each surveying transcriptional
changes resulting from a different biological context (Table S1).
Expression screening accepts as input this compendium of
microarray data as well as a given a query gene set. It then examines
each data set in the compendium and calculates for each gene, g,t h e
expression correlation between g and all other genes. The method uses
these correlations to produce a rank ordered list of g’s expression
neighbors and assesses whether the query gene set is significantly over-
represented near the top or bottom of this list using an enrichment
statistic (see Materials and Methods). This enrichment statistic,
following correction for multiple hypothesis testing, serves as a co-
expression metric between each gene and the query gene set in that
dataset. The procedure is repeated for all datasets in the compendium
to generate a co-expression matrix whose values represent each gene’s
co-expression to the query gene set within a dataset (Figure 1).
Genes that consistently co-express with the query gene set in many
independent microarrray datasets likely have a functional role in the
query pathway. We therefore sought to generate a measure of
consistent coexpression by integrating the co-expression scores for
each gene across all data sets. A key feature of the integration scheme
is that it offers a principled means of weighting the evidence from
each of the data sets. Since the query gene set may itself not be co-
expressed in all data sets, we weight data sets according to the intra-
correlation of the querygene set to ensure that experiments where the
query pathway is itself regulated have greater influence upon the final
result. Finally, we apply a data integration procedure that incor-
porates these weights to arrive at an integrated probability for each
gene summarizing its overall co-expression with the query gene set in
the microarray compendium (see Materials and Methods). Our data
integration procedure is based on the naı ¨ve Bayes scheme, which
allows independent co-expression evidence from different data sets to
strengthen each other, but is modified to be robust against outliers
[25,26]. Importantly, this procedure avoids direct comparison
between expression signals from separate data sets, which can
introduce artifacts and distort co-expression measures [27,28].
To validate the expression screening methodology, we first
applied it to the well-studied and transcriptionally-regulated
cholesterol biosynthesis pathway [29]. We manually curated a
set of 19 genes encoding established cholesterol biosynthesis
enzymes (Table S2) and applied expression screening to this set.
We were able to reconstruct the entire cholesterol biosynthesis
pathway within the top 41 high-scoring genes, a substantial
improvement over co-expression scores obtained from the best
microarray experiment alone (Figure 1B). Among the top 41 co-
expressed genes we also recovered the LDL receptor, SREBF2 and
INSIG1, three well-known regulators of this pathway (Table S3). A
key feature of expression screening is the weighting of each data set
according to the intra-correlation of the input pathway. In the case
of cholesterol biosynthesis, a variety of data sets representing many
distinct biological conditions were given high weights, consistent
with the pathway’s central role in cellular metabolism (Table S1).
Author Summary
Respiratory chain disorders represent the largest class of
inborn errors in metabolism affecting 1 in every 5,000
individuals. Biochemically, these disorders are character-
ized by a breakdown in the cellular process called
oxidative phosphorylation (OxPhos), which is responsible
for generating most of the cell’s energy in the form of ATP.
Sadly, for approximately 50% of patients diagnosed, we do
not know the molecular cause behind these disorders. One
possible reason for our limited diagnostic capability is that
these patients harbor a mutation in a gene that is not
known to act in the OxPhos pathway. We therefore
designed a computational strategy called expression
screening that integrates publicly available genome-wide
gene expression data to predict new genes that may play a
role in OxPhos biology. We identified several uncharacter-
ized genes that were strongly predicted by our procedure
to function in the OxPhos pathway and experimentally
validated two genes, SLIRP and CHCHD2, as being essential
for OxPhos function. These genes, as well as others
predicted by expression screening to regulate OxPhos,
represent a valuable resource for identifying the molecular
underpinnings of respiratory chain disorders.
Computational Discovery of OxPhos Regulators
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substantial loss of specificity (Figure S1). Thus, expression
screening is capable of identifying informative datasets in a
microarray compendium and reconstructing transcriptionally co-
regulated pathways with high precision.
Application of expression screening to the OxPhos
system
We next applied expression screening to the OxPhos pathway
using the 1427 microarray dataset compendium, and a manually
curated gene set of nuclear-encoded structural OxPhos subunits
(Figure 2A, Table S4). We excluded the mtDNA-encoded subunits
from the query set since these were not well measured by the
Affymetrix platforms. The resulting co-expression matrix
(Figure 2B) reveals the robust coordination of OxPhos gene
expression in a large variety of biological contexts. The OxPhos
gene set exhibits robust intra-correlation (weight wd.0.75) in
nearly 10% of microarray datasets present in the compendium
(Table S1). The data set weights enable us to spotlight biological
contexts in the compendium for which the modulation of OxPhos
gene expression may play an important role. Experiments with
large weights include expected conditions such as exercise
(GSE1659), Alzheimer’s disease (GSE5281) and Pgc1a over-
expression (GSE4330) as well as lesser-studied contexts including
down-regulation of OxPhos followed by recovery during time-
courses of skeletal muscle regeneration (GSE469, GSE5413).
Figure 1. Overview and validation of expression screening. (A) Given a set of transcriptionally regulated genes as input (query gene set),
expression screening interrogates a compendium of D microarray data sets (GEO) to produce a matrix of probabilities qgd of co-expression with the
query genes for each of N genes (rows) measured in D data sets (columns). Each data set is assigned a weight, wd (vertical bars), according to the
intra-correlation of the query gene set. A robust Bayesian data integration procedure is used to compute an integrated probability pg of co-
expression for each gene (horizontal bars). (B) Cross-validated receiver-operator curve reporting the recovery of the query cholesterol biosynthesis
gene set. Blue line: full expression screen data integration (1,427 data sets). Red line: the single best data set. Gray line: a data set with median weight.
doi:10.1371/journal.pgen.1000590.g001
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that are consistently co-expressed with OxPhos in the microarray
compendium (Table S5). As with the cholesterol biosynthesis
pathway, data integration better predicts known genes involved in
the OxPhos pathway when compared to the most predictive data
set alone (Figure 2C). At a specificity of 99.4%, we were able to
recover 85% of the OxPhos pathway (Figure 2C). The integration
procedure also lessens confounding correlations with functionally
distinct pathways. For example, OxPhos is frequently co-
expressed with other genes encoding mitochondrial proteins
during mitochondrial biogenesis and turnover, regardless of their
specific role in oxidative phosphorylation [30–32]. Additionally,
OxPhos gene expression may correlate with the expression of
other functionally distinct ‘‘house-keeping’’ pathways, especially
the cytosolic ribosome, since genes involved in both pathways
share a similar set of conserved promoter elements and are
controlled by an over-lapping set of transcriptional regulators
[33,34]. In agreement with these findings, we observed significant
co-expression (median integrated probability pg=0.70) of the
cytosolic ribosome with the OxPhos subunits (Figure 2D).
However, integrating co-expression across all data sets in the
microarray compendium clearly distinguished the OxPhos
pathway from other mitochondrial genes and components of
the cytosolic ribosome, demonstrating the specificity of expression
screening (Figure 2D).
We next examined the non-OxPhos genes exhibiting the highest
co-expression scores. To ensure that co-expression is conserved
among mammals, we required that a gene is co-expressed with
OxPhos when analyzing human and mouse microarray datasets
independently (pg.0.70 in both species). The top 20 non-OxPhos
genes meeting this criterion are shown in Figure 3. Several of the
non-OxPhos genes listed in Figure 3 have known metabolic roles
in oxidative metabolism such as genes encoding Kreb’s cycle
enzymes, MDH2 and SUCLG1, as well as several mitochondrial
ribosomal subunits necessary for translation of the OxPhos
subunits encoded by mtDNA. Other high-scoring genes have
never been functionally associated with OxPhos and most lack
orthologues in S. cerevisiae. It is notable that recent mass
spectrometry studies of highly purified mammalian mitochondria
have localized every protein present in Figure 3 to the
mitochondria with the exception of HINT1, TCEB2 and
MDH1, which are primarily cytosolic proteins [35–37].
Recently, two candidates identified by our expression screen,
C14orf2 and USMG5, have been co-purified with complex V,
Figure 2. The OxPhos expression screen. (A) A schematic overview of mitochondrial OxPhos. The total number of protein subunits comprising
each complex is noted below the schematic. The number of subunits encoded by mitochondrial DNA that were excluded in the OxPhos expression
screen is indicated in parentheses. (B) Co-expression matrix from the OxPhos expression screen for the mouse MG-U74Av2 chip. Each value in the
matrix represents a gene’s (rows) co-expression with OxPhos within a microarray data set (columns). (C) Cross-validated receiver-operator curve
reporting the recovery of the query OxPhos genes. Blue line: full expression screen data integration (1,427 data sets). Arrow marks the 99.4%
specificity threshold recovering 85% of the OxPhos query genes. Red line: the single best data set. Gray line: a data set with median weight. (D)
Histogram of integrated co-expression probabilities from the OxPhos expression screen. Red line: OxPhos query gene set. Green line: non-oxphos
mitochondrial genes. Blue line: cytosolic ribosome genes. Black line: all other genes.
doi:10.1371/journal.pgen.1000590.g002
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their small size and biochemical properties (,7 kD) [38,39]. While
the functions of these two proteins are still unknown, their physical
association with complex V further supports the specificity of the
expression screening results for identifying OxPhos-related genes.
Interestingly, two other uncharacterized proteins presented in
Figure 3, C1orf151 and C12orf62, are also less than 10 kD in size
(8.6 kD and 6.4 kD, respectively) and contain a single-pass
transmembrane domain similar to C14orf2 and USMG5. These
molecular similarities suggest that C1orf151 and C12orf62 may
also physically associate with OxPhos.
CHCHD2 and SLIRP are necessary for OxPhos function
To validate the results from the OxPhos expression screen, we
selected five functionally uncharacterized mitochondrial candidates
from Figure 3 for which we could obtainreliable shRNA reagents to
experimentally test their role in OxPhos function (C14orf2, USMG5,
CHCHD2, SLIRP and PARK7). For each of the five candidate genes,
we identified at least two independent, non-toxic shRNAs that
deplete mRNA abundance by more than 85% (Figure S2). We were
unable to obtain high quality shRNA reagents for other candidates
including C1orf151, C19orf20 and C12orf62.
We first silenced each candidate gene in immortalized human
fibroblasts and measured the live-cell oxygen consumption rate
(OCR) as a general parameter of basal OxPhos activity. Silencing
of two candidates, CHCHD2 and SLIRP, significantly reduced
cellular OCR by approximately 40% compared to control cells
(P,.05; Figure 4A). Additionally, a single shRNA targeting
C14orf2 reduced OCR by 35% (P,.05); however, this result
may be due to an off-target effect since a second hairpin targeting
C14orf2 did not substantially affect OCR (Figure 4A).
Inherited or acquired mutations causing OxPhos dysfunction
often destabilize or cause the misassembly of one or more of the
five complexes comprising OxPhos. We therefore assessed whether
knock-down of any of the five candidates affected complex stability
by blotting for ‘‘labile’’ OxPhos subunits whose stability depends
on their respective complex being properly assembled in the
mitochondrial inner membrane (Figure 4B). Again, we noted that
knock-down of SLIRP and CHCHD2 clearly affected OxPhos as
both dramatically reduced the abundance of the complex IV
subunit, COX2, and to a lesser extent, NDUFB8, a component of
complex I. To ensure that CHCHD2 and SLIRP are responsible for
maintaining the activities of OxPhos complexes I and IV in native
form, we measured the activity of immuno-captured preparations
of these complexes (Figure 4C and 4D) [40]. Reducing the
expression of both candidates reduced cellular CIV activity
(P,.05) while only SLIRP significantly affected CI (P,.05).
SLIRP is an RNA–binding protein that maintains
mitochondrial RNA expression
The SLIRP protein contains an RNA-binding domain and was
previously reported to associate with steroid receptor RNA
activator (SRA), a nuclear non-coding RNA, and thereby repress
the ability of SRA to activate nuclear receptors [41]. However,
SLIRP is predominantly mitochondrial [35,41]. Since the protein
is localized to the mitochondria and is able to bind RNA, we
hypothesized that it might affect OxPhos activity by directly
modulating the level of mtRNA, either through expression,
processing or stability of the mitochondrial transcripts. mtRNA
is transcribed from mtDNA in two continuous poly-cistronic
transcripts (one from each mtDNA strand), which are subsequently
processed to produce eleven OxPhos protein-encoding mRNAs,
two ribosomal RNAs (rRNA) and a full complement of tRNAs.
The processed mtRNAs are individually regulated by mtRNA
stability factors, many of which remain to be identified [42].
To determine whether SLIRP acts in the mtRNA processing
pathway, we designed a full panel of qPCR assays to measure the
abundance of each protein-coding and ribosomal mtRNA
transcript (Table S5). We again used shRNA to reduce SLIRP
expression and measured the resulting effect on each mtRNA
transcript. Knock-down of SLIRP significantly reduced the
abundance of all eleven protein-encoding mtRNA transcripts
Figure 3. Top scoring genes in the OxPhos expression screen. Left, bar plot indicating the ranks of each OxPhos query gene by descending
probability pg, as well as a magnified view of the 1,000 highest-ranking genes. The table displays the top 20 non-OxPhos genes resulting from the
expression screen (corresponding to the top 73 genes including OxPhos).
doi:10.1371/journal.pgen.1000590.g003
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(Figure 5B). The most pronounced mtRNA reduction was seen for
transcripts encoding complex IV subunits as well as the bi-cistronic
transcript encoding the ND4 and ND4L subunits of complex I,
which is concordant with the specific complex I and IV
biochemical defects shown in Figure 4. The effect of SLIRP
depletion upon mtRNA appears specific to the protein-encoding
mtRNA transcripts since it did not affect the expression of the 12S
or 16S mitochondrial rRNAs (Figure 5A), even though these
rRNAs are encoded on the same primary poly-cistronic transcript
that contains all but one of the mitochondrial mRNAs. To assess
whether this regulation of mtRNA by SLIRP is conserved among
mammals, we also silenced the gene encoding the mouse ortholog
of SLIRP in C2C12 myoblasts. We again observed down-
regulation of all three complex IV-encoding mtRNAs (Figure S3).
Since SLIRP is proposed to be alternatively localized to the
nucleus, we wondered whether it might affect mtRNA expression
indirectly by regulating the nuclear expression of known mtDNA
transcription factors or mtRNA regulators. However, shRNA
targeting SLIRP did not significantly alter the expression of known
nuclear-encoded mtRNA regulators TFAM, TFB1M, and TFB2M,
nor did it affect the expression of the nuclear-encoded OxPhos
subunit UQCRC1, further suggesting that SLIRP acts within the
mitochondria to regulate mtRNA abundance (Figure S4). Finally,
we investigated whether over-expression of SLIRP would be
sufficient to boost mtRNA abundance in the cell. Over-expressing
SLIRP for 48 hours did not alter mtRNA abundance, but over-
expression did rescue the down-regulation of mtRNA resulting
from knock-down of SLIRP in human cells. Besides demonstrating
that the over-expression construct is functional and that the
shRNA is on-target, this indicates that SLIRP is not a limiting
factor for mtRNA abundance in wild-type cells (Figure 5C).
The SLIRP protein depends upon mtRNA for its own
stability
Since adequate expression of SLIRP is essential for maintaining
mtRNA levels, we asked whether SLIRP is transcriptionally
regulated in response to a depletion of mtRNA. We used ethidium
bromide (EtBr), a DNA-intercalating agent that is selectively
absorbed by mitochondria and reduces mtDNA copy-number
Figure 4. Silencing CHCHD2 and SLIRP disrupts OxPhos function. (A) Oxygen consumption rate (OCR) of MCH58 human fibroblasts measured
at 10–14 days post-infection with empty vector, shRNA targeting GFP, or two independent shRNAs targeting each of five candidates from the OxPhos
expression screen. Values are reported as percent of empty vector sample’s OCR and represent means of 20 replicate wells. Error bars indicate the
95% normal confidence interval. (B) Western blot of cleared whole cell lysate harvested 10–14 days post-infection, subjected to SDS-Page and blotted
for labile markers of each OxPhos complex. shRNA targets are indicated below each lane and blotted proteins are indicated to the right with their
respective OxPhos complex in parentheses. EtBr represents a positive control sample from cells treated with 40 ng/ml ethidium bromide for 4 days.
(C, D) Assays for activity of complexes I and IV in whole-cell native protein harvested from MCH58 cells infected in triplicate with shRNAs targeting
SLIRP, CHCHD2 (two independent shRNAs each) or GFP. Values are reported as percent of activity for shRNA targeting GFP. Error bars represent
standard deviation. *, P,0.05 (n=3, two-tailed unpaired t-test).
doi:10.1371/journal.pgen.1000590.g004
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EtBr for four days, we didnot observe any compensatory increase in
SLIRP expression as mtDNA and mtRNA were depleted in a
concentration-dependent manner (Figure 6A). Surprisingly, how-
ever, we did observe a dramatic reduction in SLIRP at the protein
level, in a manner depending on the concentration of EtBr
(Figure 6B). This suggests that the stability of SLIRP depends upon
either mtDNA copy-number or mtRNA abundance. A similar
phenomenon has been previously reported for TFAM, a critical
regulator of both mitochondrial DNA and RNA [30]. TFAM coats
the mtDNA to protect it from degradation but TFAM is also
dependent upon mtDNA for its own protein stability [44]. We
wonderedwhetherSLIRP,beinganRNA-binding protein,depends
exclusively upon mtRNA for its stability. To assess whether mtRNA
rather than mtDNA quantity is important for stabilizing SLIRP we
used shRNA to deplete cells of LRPPRC, a mitochondrial protein
necessary for maintaining mtRNA expression but not mtDNA
copy-number [45] (Figure 6C). We again observed a substantial
drop in SLIRP protein abundance, likely indicating a mutual
partnership between SLIRP and mtRNA where each is responsible
for the other’s stability within the mitochondria (Figure 6D).
Discussion
To predict novel OxPhos regulators we have developed a
method called expression screening, which utilizes the inherent
strong transcriptional co-expression of the known OxPhos
structural subunits to identify other genes sharing similar
expression profiles in a compendium of microarray data. While
co-expression analysis alone cannot fully distinguish functionally
relevant co-regulation from mere correlation, we have demon-
strated that the integration of evidence from hundreds of biological
contexts significantly enhances predictive power. In this manner,
we were able to build a reliable classifier for membership in the
OxPhos pathway that will be a useful resource for prioritizing
candidate genes in patients with respiratory chain disorders.
Figure 5. SLIRP maintains mitochondrial mRNA. (A) Expression levels of mitochondrial transcripts in MCH58 cells measured by qPCR 10 days
post-infection with either control shRNA (shGFP) or shRNA targeting SLIRP. Values are reported as fold change over shGFP-treated cells, in each case
normalized to HPRT as an endogenous control, and represent means (n=3). All values except 16S and 12S were significantly decreased compared to
shGFP (P,.05, two-tailed unpaired t-test). (B) mtDNA copy-number per cell measured by qPCR using genomic DNA from the samples in (A). Values
represent mean mtDNA/nuclear DNA ratio (n=3). (C) COX1 expression measured by qPCR in MCH58 cells infected with shSLIRP or shGFP. Labels LacZ
and SLIRP indicate cells transfected with constructs to over-express LacZ or human SLIRP, respectively. Values reported are mean ratios over
LacZ+shGFP (n=3). Error bars indicate standard deviation. *, P,.05 (two-tailed unpaired t-test).
doi:10.1371/journal.pgen.1000590.g005
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terized genes as novel regulators of the OxPhos pathway. Of these,
CHCHD2 and SLIRP resulted in clear OxPhos deficits when
targeted by shRNA. CHCHD2 is a member of a family of proteins
containing the CHCH domain (coiled-coil-helix-coiled-coil-helix;
PFAM#06747). Conserved cysteines within this motif have
previously been implicated in metal coordination or transport
suggesting that CHCHD2’s role in stabilizing complex IV may be
related to regulation of the complex IV copper centers [46].
Interestingly, the CHCH domain is also found in an OxPhos
complex I subunit, NDUFA8, and in another Complex IV
assembly factor, COX19 [46,47]. Further study of this important
domain should lend insight to the assembly and function of
OxPhos.
Silencing of some high-scoring expression screening candidates
including USMG5, C14orf2 and PARK7 did not result in an
oxidative phenotype. These outcomes may reflect common caveats
with shRNA experiments including insufficient protein knock-
down, functional redundancy or lack of the proper experimental
context. For example, our expression screen implicates the gene
PARK7, named for causing Parkinson’s disease when mutated, as a
key player in OxPhos biology. Currently, there is no established
role for PARK7 in the OxPhos pathway [48]. While we did not
observe an effect on basal oxygen consumption when perturbing
PARK7 expression in our cell line, PARK7 protein may still be an
important OxPhos regulator that acts in a context-dependent
manner. Others have reported PARK7 to act as an antioxidant
that scavenges mitochondrial radical oxygen species, a harmful by-
product of an active OxPhos system [49]. Additionally, cells
depleted of PARK7 are hyper-sensitive to rotenone treatment, a
potent complex I inhibitor [50].
SLIRP is consistently co-expressed with the nuclear OxPhos
machinery and regulates the abundance of the mitochondrial
protein-encoding transcripts. These properties raise the interesting
possibility that SLIRP is co-regulated with the nuclear OxPhos
genes in order to coordinate nuclear and mitochondrial OxPhos
gene expression. This phenomenon has also been previously
reported for genes encoding the mtDNA transcription factors:
TFAM, TFB1M and TFB2M [51,52]. In certain biological
contexts, these genes have been noted to be co-expressed with
nuclear OxPhos genes [51,52]. In our expression screen, we did
observe co-expression of these factors with OxPhos in certain
microarray experiments, but this co-expression was not frequent
enough to generate a high score in the overall data integration. In
contrast, SLIRP scored among the top 20 genes in the genome for
its co-expression with OxPhos (Figure 3), strongly implicating a
role for SLIRP in synchronizing nuclear and mitochondrial gene
expression.
The precise molecular mechanism by which SLIRP maintains
mtRNA is not yet clear. To date, most studies of mtRNA
maintenance has focused upon the core transcriptional machinery
responsible for transcribing the primary poly-cistronic transcripts.
This essential machinery includes the mitochondrial polymerase,
POLRMT and its partner MRPL12, as well as the transcription
Figure 6. SLIRP depends upon mitochondrial mRNA for stability. (A) mtDNA copy-number, mtND2 expression (mtRNA), and SLIRP expression
measured by qPCR from MCH58 cells depleted of mtDNA for 4 days in the presence of 2.5, 5, 10, or 20 ng/ml ethidium bromide. (B) Western blot of
SLIRP, COX2, and ACTB protein abundance for the samples in (A). (C) mtDNA copy-number and mRNA expression of COX2 and LRPPRC in MCH58 cells
infected with shRNA targeting LRPPRC or a GFP control. Mean ratios over shGFP cells are reported (n=3). (D) Western blot of protein lysates from
shGFP-, shSLIRP-, and shLRPPRC-infected cells 10 days post-infection.
doi:10.1371/journal.pgen.1000590.g006
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mammalian mtRNA post-transcriptional processing and stability
remain unknown [24]. For example, a human mitochondrial
poly(A) polymerase (mtPAP) has been recently identified [53], but
this protein does not contain an obvious RNA-binding domain,
suggesting that it requires one or more currently unidentified
RNA-binding partners [24]. Additionally, in S. cerevisiae, several
mitochondrial RNA-binding proteins stabilize mtRNA transcripts,
but proteins with similar functions have not been found in
mammals [54–56]. Given its involvement in maintaining mtRNA
it is tempting to speculate that SLIRP fulfills one or more of these
roles in mammalian mtRNA biology. SLIRP joins a small cast of
RNA-binding mitochondrial proteins that are responsible for
maintaining steady-state mtRNA in human cells: LRPPRC,
SUPV3L1 and PTCD2 [45,57,58]. LRPPRC is of central
importance for OxPhos function, and patients harboring muta-
tions in LRPPRC develop the French-Canadian variant of Leigh
syndrome, a devastating hepatocerebral metabolic disorder [11].
In our study, shRNA targeting SLIRP phenocopies mutations in
LRPPRC by causing loss of mtRNA and a significant reduction in
complex IV activity. Given these similarities, SLIRP should be
considered a candidate gene for respiratory chain disorders.
Many of the proteins encoded by the human genome are still
functionally uncharacterized and methods such as expression
screening will be useful in closing the gaps in our knowledge of
cellular pathways [59]. While we have applied expression
screening to the cholesterol biosynthesis and OxPhos pathways,
this technique is readily extendible to any gene set exhibiting
transcriptional co-regulation. In a separate study we show the
utility of this method in identifying new mitochondrial proteins
important for heme biosynthesis [60]. Expression screening is not
the only tool that should be considered for functional prediction.
Network-based integration of protein-protein interaction data and
other data integration methods have also been successfully applied
to predict the functions of uncharacterized proteins [19,61,62].
Combining expression screening with these or other methods
could possibly yield more accurate predictions, especially in cases
where transcriptional regulation may not be the dominant mode of
regulatory control. Still, microarray gene expression data has
several advantages: it is by far the most abundant data source
available, offers a more unbiased approach than most techniques,
and permits investigating gene function in specific biological
contexts. As public repositories of microarray data continue to
grow at an accelerating pace, we anticipate that expression
screening will become an increasingly important tool for
discovering gene function.
Materials and Methods
Expression screening
A total of 2,052 mouse and human microarray data sets were
downloaded from the NCBI Gene Expression Omnibus [18] in
March 2008 for the Affymetrix platforms HG-U133A (GEO
GPL96), HG-U133+ (GEO GPL570), MG-U75Av2 (GEO
GPL81), Mouse430A (GEO GPL339) and Mouse430 (GEO
GPL1261). We discarded data sets with less than 6 arrays as well
as data sets containing multiple tissues. We then merged
overlapping data so that no two data sets shared identical arrays,
resulting in a final compendium of D=1,427 data sets. For a given
query gene set S, each data set d and each gene g, we calculated the
vector of Pearson correlation coefficients rgj between g and all other
genes j. We then define the correlation between g and S as the
GSEA-P enrichment score (ES) statistic [63] with g as the
‘‘phenotype’’ variable and N representing the total number of
genes.
ESgd~ max
1ƒiƒn
X
j[S:jƒi
rgj
       
NS
{
j[ =S : jƒi fg jj
N{ S jj
         
         
, NS~
X
j[S
rgj
       
We next calculated randomized enrichment scores ES
0 by
randomly permuting values (arrays) for gene g, re-calculating rgj
and applying the above formula. We pooled N0=100,000
permuted ES
0 values from all N genes to estimate the marginal
null distribution of enrichment scores. From this we estimated the
global false discovery rate (FDR) of each actual ES value [63,64] as
the ratio of tail probabilities:
FDRgd~
j : ES
0
jd§ESgd
no      
     
.
N0
j : ESjd§ESgd
           
N
We take qgd=12FDRgd to represent the probability of co-
expression of gene g with the query gene set S in data set d. The
data set weights wd were defined as the average of qgd across the
query genes. We then integrated these probabilities using a robust
Bayesian formula [25] to obtain a final probability pg of co-
expression of gene g with the query gene set,
pg~
pD{1
0 Pd p0zwd qgd{qd
     
pD{1
0 Pd p0zwd qgd{qd
     
z 1{p0 ðÞ
D{1Pd 1{p0{wd qgd{qd
     
where qd is the average of qgd in data set d. This method of data
integration assumes conditional independence between data sets
given the co-expression hypothesis, which allows concurring
evidence from multiple data sets to reinforce each other in
calculating the integrated probability. Incorporating the prior p0
affords some robustness to outliers in terms of qgd values close to 0
or 1, which can arise from the permutation-based FDR estimation.
For the OxPhos expression screen the prior p0 was set to 5%,
roughly corresponding to the fraction of mitochondrial genes in
the genome [35]. Since the query genes are used to calculate the
weights wd, the sensitivity and specificity was estimated using leave-
one-out cross-validation, with one gene withheld from the weights
calculation in each iteration.
Mapping genes to Affymetrix probesets
We mapped Affymetrix probesets to NCBI Homologene
identifiers using a previously described method [65]. For the
query gene sets (OxPhos and cholesterol pathways) we validated
each gene’s mapping by Blast. It is important that each query gene
is represented only once in the gene set. For cases in which
multiple Affymetrix probesets map to a gene in the query gene set,
we chose the probeset with the least potential for cross-
hybridization according to Affymetrix probeset annotations.
Specifically, we used the following Affymetrix probeset suffix
hierarchy (‘at’.‘a_at’.‘s_at’.‘x_at’). In cases where there were
ties, we chose the lower numbered probeset to represent a gene.
We performed expression screening as described above
separately for each microarray platform, using Affymetrix
probeset-level data. When integrating across all array platforms,
we chose for each Homologene identifier the probeset with
maximal pg in the platform-specific screen. We then re-integrated
across all data sets, ignoring missing values, to produce the final list
of probabilities, pg (Figure 3, Table S3, Table S5).
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MCH58 immortalized human fibroblasts were kindly donated
by Eric Shoubridge [66]. 293T and C2C12 cells were received
from the American Type Culture Collection (CRL1772 &
CRL11268). Unless otherwise indicated, all experiments were
carried out in DMEM, 4.5 g/L glucose, 10% FBS (Sigma #2442)
supplemented with 2 mM glutamine, 100 I.U Penicillin and
100 ug/ml Streptomycin.
shRNA lentivirus production and infection
Lentiviral vectors for expressing shRNA (pLKO.1) were received
from the Broad Institute’s RNAi Consortium or from Open
Biosystems. Unique identifiers of each shRNA construct can be
found in Figure S1. Procedures and reagents for virus production
are adapted from the Broad Institute’s RNAi Consortium protocols
[67]. Briefly, 400,000 293T cells were seeded in a 24-well dish and
12 hr later triple-transfected with pLKO.1-shRNA, a packaging
plasmid (pCMV-d8.91) and a pseudotyping plasmid (pMD2-VSVg)
using Fugene6 reagent at 3:1 (reagent:DNA) (Roche
#11815091001). Media was refreshed 18 hr post-transfection,
supplemented with 1% BSA and virus collected 24 h later. For
infection, 30,000 cells were seeded in a 24-well dish. 30 ul viral
supernatant was added to cells for a final volume of 500 ul media
containing 8 ug/ml polybrene (Sigma #H9268). The plates were
spun 800rcf for 30 min at 32uC, returned to 37uC and 24 h post-
infection were selected for infection with 2 ug/ml puromycin
(Sigma #P9620). RNA for assessing knock-down efficiency was
isolated 7–10 days post-infection.
cDNA and qPCR
RNA was isolated using the RNeasy system (Qiagen #74106)
with two repetitions of DNAse digestion to remove mtDNA and
genomic DNA from the sample. 1 ug of RNA was used for 1
st-
strand cDNA synthesis using a mix of poly(dT) and random
hexamer primers (SuperScript III, Invitrogen, #18080). Genomic
DNA used for the analysis of mtDNA quantity per cell was isolated
using Qiagen DNeasy system. 1 ng genomic DNA was used for
multiplex qPCR analysis to simultaneously measure nuclear DNA
and mtDNA (See Table S6 and [68]). qPCR of cDNA and
genomic DNA was performed using the 96-well ABI7500 qPCR
system in 20 ul reactions prepared with 26 master-mix (ABI
#4369510), the appropriate 206 ABI taqman assay (Table S6)
and diluted cDNA sample.
SLIRP over-expression
A pDONR-221 Gateway clone for SLIRP, used previously by
our laboratory for cellular localization studies [35], was sequence
verified and cloned into a pcDNA destination vector in-frame with
a C-terminal V5-His tag (pDEST40, Invitrogen #12274-015).
293T cells were infected with validated shRNAs targeting either
SLIRP or GFP as described above. Seven days post-infection,
400,000 cells were seeded in a 24-well dish and transfected with
either pcDNA-LacZ-V5-His or pcDNA-SLIRP-V5-His. 48 hrs post-
transfection, cells were harvested for downstream analyses.
Live-cell oxygen consumption measurements
Live-cell oxygen consumption readings (OCR) were performed
using a 24-well Seahorse XF24 Bioflux analyzer. MCH58 cells
were seeded at a density of 30,000/well in unbuffered media
(4.5 g/L glucose, 4 mM glutamine, 1 mM pyruvate in DMEM,
pH 7.4). The XF24 analyzer was set to read OCR/well as an
average of four 3 min measurements with a 1 min mixing interval
between measurements. Each plate contained four different
samples of five replicates each with one sample always being the
shRNA vector control (pLKO.1) that was used for normalization
and comparison between experiments. Each ‘‘batch’’ of four
samples was measured on four different plates summing to 20
replicates per sample. Samples were randomized within each plate
to avoid plate-position effects and experiments were repeated
multiple times to ensure reproducibility. To correct for cell seeding
errors, we measured the total protein content per well after each
experiment (BCA method) and normalized the OCR per well by
dividing by the corresponding protein concentration.
Immunoblotting
5 ug of cleared whole cell lysate isolated in RIPA buffer was
used per lane on a 4–12% Bis-Tris gel (Invitrogen, #NP0321) and
blotted on a PVDF membrane (Invitrogen, #LC2005) using a
semi-dry transfer apparatus (Bio-Rad), 15 V, 20 min. Membranes
were blocked for 2 hr at room temperature in tris-buffered-saline
solution (Boston BioProducts #BM300) with .1% Tween-20 and
5% BSA (TBS-T-BSA). Primary antibodies were incubated with
the membrane overnight at 4uC in TBS-T-BSA at the dilutions
reported in Table S7. Secondary sheep-anti-mouse (GE-Health-
Care, #na931v) or sheep-anti-rabbit (GE-HealthCare, #na934v)
antibodies were incubated with the membrane at a 1:5,000
dilution in TBS-T-BSA for 45 min at room temperature. The
membrane was developed using Super Signal West Pico (Pierce,
#34077).
OxPhos Complex I and IV activity measurements
Complex I and Complex IV Dipstick activity assays were
performed on 20 ug and 25 ug cleared whole cell lysate,
respectively, according to the manufacturer’s protocol (Mitos-
ciences #MS130 and #MS430). 30 ul of lysis buffer A was used
per 500,000 cells for lysis and solubilization.
Supporting Information
Figure S1 Validation of data set weighting. ROC curve
comparing the original formulation of expression screening for
the cholesterol gene set (blue line) versus a screen using uniform
weights (red line).
Found at: doi:10.1371/journal.pgen.1000590.s001 (0.34 MB PDF)
Figure S2 Validation of gene silencing by RNAi. mRNA
expression in MCH58 human fibroblasts infected with lentivirus
to over-express shRNAs targeting each candidate gene (see
Materials and Methods). RNA was isolated 5–7 days post-infection
and used to produce cDNA for measuring RNAi efficiency by
qPCR (see Materials and Methods). Each column represents an
independent shRNA hairpin targeting the indicated gene.
Hairpins are labeled by their official Broad Institute RNAi
consortium identifiers. Reported values are normalized to RNA
from uninfected cells. Error bars represent the range of the
duplicate measurements. Arrows indicate the best two shRNAs for
each gene which were used for downstream experiments.
Found at: doi:10.1371/journal.pgen.1000590.s002 (0.56 MB PDF)
Figure S3 Silencing the SLIRP homologue in mouse cells
reduces mtRNA expression. (A) mRNA expression levels of
C2C12 mouse myoblasts infected with shRNA targeting different
regions of 1810035L17Rik, the mouse homologue of SLIRP. RNA
was isolated five days post-infection and 1810035L17Rik mRNA
abundance was measured by qPCR. Error bars represent the
range of duplicate measurements. (B) mRNA levels for Actin,
1810035L17Rik, COX1, COX2, and COX3 in C2C12 mouse
myoblasts infected with shRNA TCRN0000103890 targeting
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PLoS Genetics | www.plosgenetics.org 10 August 2009 | Volume 5 | Issue 8 | e10005901810035L17Rik. Values are given as ratios over shGFP-treated
cells. mtDNA quantity was measured from genomic DNA isolated
simultaneously with RNA. Error bars represent standard deviation
(n=3). *, P,.05 (two-tailed unpaired t-test).
Found at: doi:10.1371/journal.pgen.1000590.s003 (0.33 MB PDF)
Figure S4 Silencing SLIRP does not affect UQCRC1, TFAM,
TFB1M,o rTFB2M expression. mRNA levels of UQCRC1, TFAM,
TFB1M, and TFB2M measured by qPCR from the samples
described in Figure S2. SLIRP_A and SLIRP_B are independent
shRNA hairpins corresponding to Figure S2 samples
TRCN0000152814 and TRCN0000154330, respectively. Results
were normalized to the expression of HPRT as an endogenous
control. Values are reported as average ratio over shGFP; error
bars indicate standard deviation (n=3).
Found at: doi:10.1371/journal.pgen.1000590.s004 (0.15 MB PDF)
Table S1 Microarray data sets used in expression screening.
Each microarray data set is listed with its GEO accession number,
the data set title and Affymetrix platform. Mouse platforms are
preceded by ‘‘MG’’ while human platforms are preceded by
‘‘HG’’. Each data set is also listed with its ‘‘weight’’ representing
the intra-correlation of either the OxPhos gene set or cholesterol
pathway gene set (see Materials and Methods).
Found at: doi:10.1371/journal.pgen.1000590.s005 (0.28 MB
XLS)
Table S2 The cholesterol pathway gene set used in expression
screening. Genes directly involved in cholesterol biosynthesis were
mapped to each Affymetrix platform. In cases where multiple
probesets match a gene, we chose the probeset exhibiting the least
cross-hybridization at the sequence level according to Affymetrix
annotations.
Found at: doi:10.1371/journal.pgen.1000590.s006 (0.02 MB
XLS)
Table S3 Results of the cholesterol biosynthesis expression
screen. The top 41 genes resulting from the cholesterol expression
screen sorted by their probability of co-expression with the
cholesterol gene set after data integration of all human and mouse
microarray data sets (‘‘Human&Mouse’’ column). We also include
the probabilities resulting from data integration of each platform
alone or of each species, human or mouse, alone. The Affymetrix
probeset yielding the highest probability of co-expression for each
gene is given for each platform. Genes are identified by their
NCBI homologene ID (HID). Cholesterol pathway genes used as
the query gene set are identified by a ‘‘1’’ in the ‘‘Cholesterol’’
column.
Found at: doi:10.1371/journal.pgen.1000590.s007 (0.03 MB
XLS)
Table S4 The OxPhos pathway query gene set. Genes
previously validated as structural subunits of OxPhos (‘‘citation’’
column) were mapped to Affymetrix platforms (see Materials and
Methods). Genes used in the query set of expression screening are
marked by an asterisk. Some OxPhos structural subunits are
encoded by the mitochondrial genome and are not well measured
by Affymetrix platforms. Additionally, some subunits are tissue
specific or are only present in either human or mouse. These are
shown in the table but were not included in the query gene set.
Found at: doi:10.1371/journal.pgen.1000590.s008 (0.05 MB
XLS)
Table S5 Results of the OxPhos expression screen. For each
gene, we report the probability of co-expression with the OxPhos
gene set after data integration of all human and mouse microarray
data sets (‘‘Human&Mouse’’ column). We also include the
probabilities resulting from data integration of each platform
alone or from human or mouse alone. The Affymetrix probeset
yielding the highest probability of co-expression for each gene is
given for each platform in the rightmost columns. When there is
no probeset listed for a gene in a particular platform, that gene is
not measured by the platform and the platform is not included in
the data integration procedure. Genes are identified by their
NCBI homologene ID (HID) and Entrez gene symbol. OxPhos
genes used in the query gene set are identified by a ‘‘1’’ in the
‘‘OxPhos’’ column.
Found at: doi:10.1371/journal.pgen.1000590.s009 (5.74 MB
XLS)
Table S6 Taqman qPCR assay information.
Found at: doi:10.1371/journal.pgen.1000590.s010 (0.02 MB
XLS)
Table S7 Antibodies used in this study.
Found at: doi:10.1371/journal.pgen.1000590.s011 (0.01 MB
XLS)
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